Home
(Not that I am recommending you ignore the heart of modern medicine the labs tests, but be careful. There is no evidence that getting you into the medical systems for most important diseases saves lives. Maybe is because the treatments they provide don't work and many times make things worse by over medication, but the truth is there is no evidence they provide any longevity benefit. The medical establishment love them since they provide the opportunity to make everyone a "patient".)
http://www.alphagalileo.org/ViewItem.aspx?ItemId=148775&CultureCode=en
Professor John Ioannidis, senior author on the paper, says: “Our comprehensive overview shows that documented reductions in disease-specific mortality in randomized trials of screening for major diseases are uncommon. Reductions in all-cause mortality are even more uncommon. This overview offers researchers, policy-makers, and health care providers a synthesis of RCT evidence on the potential benefits of screening and we hope that it is timely in the wake of recent controversies.”
The researchers argue that randomised evidence should be considered on a case-by-case basis, depending on the disease, adding that screening is likely to be effective and justifiable for a variety of other clinical outcomes besides mortality. “However,” they conclude, “our overview suggests that expectations of major benefits in terms of reductions in mortality from screening need to be cautiously tempered”.
http://www.alphagalileo.org/ViewItem.aspx?ItemId=148775&CultureCode=en
Professor John Ioannidis, senior author on the paper, says: “Our comprehensive overview shows that documented reductions in disease-specific mortality in randomized trials of screening for major diseases are uncommon. Reductions in all-cause mortality are even more uncommon. This overview offers researchers, policy-makers, and health care providers a synthesis of RCT evidence on the potential benefits of screening and we hope that it is timely in the wake of recent controversies.”
The researchers argue that randomised evidence should be considered on a case-by-case basis, depending on the disease, adding that screening is likely to be effective and justifiable for a variety of other clinical outcomes besides mortality. “However,” they conclude, “our overview suggests that expectations of major benefits in terms of reductions in mortality from screening need to be cautiously tempered”.
